A Phase 4 interventional study of Fingolimod and Disease Modifying therapy in Relapsing Remitting Multiple Sclerosis, sponsored by Novartis Pharmaceuticals. Completed at 123 sites in 2 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2021-01-05.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies testing fingolimod in Multiple Sclerosis, Relapsing-Remitting — none open to participants now, 1 under way, none of them phase 3. fingolimod · Multiple Sclerosis, Relapsing-Remitting.
Among the 19 studies testing fingolimod in Multiple Sclerosis, Relapsing-Remitting, this one is the 4th largest by enrollment, is one of 4 that started in 2012, is one of 14 in phase 4, and was the 11th registered.
618 studies on the registry are indexed under Multiple Sclerosis, Relapsing-Remitting; 83 are open to participants now.
Browse Multiple Sclerosis, Relapsing-Remitting studies →None of the 19 studies testing fingolimod in Multiple Sclerosis, Relapsing-Remitting is open now. The open studies under Multiple Sclerosis, Relapsing-Remitting, anywhere →
fingolimod: first FDA approval 2010 (GILENYA), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →
Of the 60 Multiple Sclerosis, Relapsing-Remitting studies recruiting now, 11 (18%) set no upper age limit and 43 (72%) stop at 75 or younger; 2 take children under 18; 11 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 4 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 881 is above the median of 66 across 437 interventional studies indexed under Multiple Sclerosis, Relapsing-Remitting.
Median enrollment 142 across the 19 interventional studies. Of the 16 that completed or were terminated, 12 (75%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 19 have an industry lead sponsor. The 5 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
34 studies in Multiple Sclerosis, Relapsing-Remitting by Novartis: 1 open now, 4 under way, none of them phase 3. Of 28 finished, 19 (68%) have results posted.
Among the 34 studies in Multiple Sclerosis, Relapsing-Remitting by Novartis, this one is the 4th largest by enrollment of the 26 interventional ones that give a count, is one of 4 that started in 2012, is one of 15 in phase 4, and was the 15th registered.
Novartis’s Multiple Sclerosis, Relapsing-Remitting studies by the year they started, since 2006.
None of the studies under way reaches primary completion within a year.
Among the 19 studies testing fingolimod in Multiple Sclerosis, Relapsing-Remitting, from their registry updates:
Among Novartis’s 34 in Multiple Sclerosis, Relapsing-Remitting:
This tab as a report to print or save as PDF → With an account.
A 12 month study where 852 patients with relapsing remitting MS will be randomized 1:1 to fingolimod or approved disease modifying therapy. Patients will be be treatment naive or have only been treated with one class of DMT (Interferon beta preparation or glatiramer acetate) . Patients will be able to switch to different treatment for safety, efficacy, tolerability or convenience during the study.
Primary objective is to evaluate efficacy of fingolimod by assessing patients retention on treatment. Secondary objectives are to compare reasons for discontinuation, adverse events, cognitive impairment, medication satisfaction and change in brain volume measured by MRI.
852 Patients with relapsing remitting MS will be randomized 1:1 to fingolimod or approved first line DMTs. Patients must be either treatment naive or have received treatment with only one class of treatment (interferon beta preparation or glatiramer acetate) . Patients previously treated with DMT and randomized to the DMT arm may not remain on the same treatment for the study and will have to switch to a different class (i.e., previously treated with glatiramer acetate will switch to interferon beta preparaption, previously treated with interferon beta preparation will swtich to glatiramer acetate).
Entry criteria at screening include but are not limited to, age 18-65, diagnosis with RRMS, EDSS \< or equal to 6, not pregnant or planning pregnancy and women of childbearing potential willing to use contraception throughout the study.
Exclusion criteria include but are not limited to - prior exposure to fingolimod, history of malignancy within 5 years, other than RRMS types of MS, other diseases of the immune system, active macular edema, systemic bacterial, viral or fungal infections, patients without vaccine against varicella zoster, receipt of live or attentuated vaccines within a month of screening, history of various cardiac conditions, presence of certain ECG abnormalities, resting heart rate \< 45 bpm, symptomatic bradycardia, recurrent syncope, severe untreated sleep apnea, severe pulmonary conditions, various hepatic conditions, certain neurologic disorders, pregnancy.
Patients may switch treatment before 3 months for safety reasons only, after 3 months for safety, efficacy, tolerability or convenience. Treatment switch during the study may be to any of study approved treatments irrespective of prior treatment.
Patients randomized to fingolimod will need to have 6 hours of observation for signs and symptoms of bradycardia following administration of the first dose. Extended observation or overnight observation may be necessary under certain circumstances. Primary objective is to evaluate efficacy of fingolimod by assessing patients retention on treatment. Secondary objectives are to compare reasons for discontinuation, adverse events, cognitive impairment, medication satisfaction and change in brain volume measured by MRI. Exploratory objectives include annualized relapse rate, OCT, MRI evaluations, biomarkers and patient reported outcome measures.
Inclusion Criteria:
Before entry women must be:
<!-- -->
Patients who have been treated with:
Patients with a history of the following cardiovascular conditions:
Patients with any of the following hepatic conditions:
Patients with the following neurological/psychiatric disorders:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Fingolimod
2 classes - Interferon Beta preparation (Exctavia, Betaseron, Rebif, Avonex) or glatiramer acetate (Copaxone)
Drug: Disease Modifying therapy
Participant Retention Rate Over 12 Months
Comparison effectiveness of fingolimod versus approved first-line disease modifying therapies by measuring the rate of participant retention on randomized treatment over a 12-month period (Full analysis set)
Time frame: at 12 months
Primary and Secondary Reasons for Discontinuation From Randomized Treatment: Randomized Set
Reasons for discontinuation in participants treated with fingolimod vs. DMT over 12 months of treatment Total discontinued (Primary reason): Fingolimod arm: 27, MS-DMT arm: 27 = 54 participants Total discontinued (Secondary reason): Fingolimod arm: 257, MS-DMT arm: 256 = 513 participants Throughout the study, investigators evaluated each patient for occurrence of randomized treatment discontinuation and determined the primary and secondary reasons for such discontinuation. At every visit, the investigator evaluated the patients and determined if they should continue on randomized treatment or change to alternative treatment. Treatment discontinuation was a clinically meaningful measure related to safety, efficacy, and tolerability over time, reflecting the therapeutic effectiveness of study treatment.
Time frame: at 12 months
Change From Baseline of Symbol Digit Modalities Test (SDMT) Scores (Oral Test) by Visit (Randomized Treatment / Randomized Phase)
Summary statistics Compare cognitive impairment measured by Symbol Digit Modalities Test (SDMT) scores. The SDMT score and its change from baseline value were summarized by visit. For the change from baseline values at each visit, ANCOVA adjusted for treatment naivety, corresponding baseline values, and age was performed for treatment comparisons The SDMT measures the time to pair abstract symbols with specific numbers. The test requires elements of attention, visuoperceptual processing, working memory, and psychomotor speed. The score is the number of correctly coded items from 0-110 in 90 seconds. The total score provides a measure of the speed and accuracy of symbol-digit substitution. NOTE: Higher scores indicate better performance.
Time frame: baseline, 6 months, 12 months, and Last assessment which is either at Month 12 or at early discontinuation
Change From Baseline of Symbol Digit Modalities Test (SDMT) Scores (Written Test) by Visit (Randomized Treatment / Randomized Phase)
Summary statistics Compare cognitive impairment measured by Symbol Digit Modalities Test (SDMT) scores. The SDMT score and its change from baseline value were summarized by visit. For the change from baseline values at each visit, ANCOVA adjusted for treatment naivety, corresponding baseline values, and age was performed for treatment comparisons The SDMT measures the time to pair abstract symbols with specific numbers. The test requires elements of attention, visuoperceptual processing, working memory, and psychomotor speed. The score is the number of correctly coded items from 0-110 in 90 seconds. The total score provides a measure of the speed and accuracy of symbol-digit substitution. NOTE: Higher scores indicate better performance.
Time frame: baseline, 6 months, 12 months, Last assessment which is either at Month 12 or at early discontinuation
Percent Change From Baseline in Brain Volume From Month 12 to Last Visit (Randomized)
Summary statistics for percent change from month 12 in brain volume by visit (Randomized treatment / randomized phase) in patients treated with fingolimod vs.DMTs as measured by MRI
Time frame: 12 months, and Last assessment which is either at Month 12 or at early discontinuation
Number of Satisfied Participants Per Medication Satisfaction Questionnaire (MSQ) Score
Summary statistics for Medication Satisfaction Questionnaire\[Question: "Overall, how satisfied are you with your current medication?"\] (Randomized treatment / randomized phase): Fingolimod vs MS-DMT
Time frame: Baseline, 1 month, 3 months, 6 months, 9 months, at 12 months & Last assessment during randomized phase which is either at Month 12 or at early discontinuation
62 Fingolimod arm participants discontinued: 57 discontinued before treatment switch, and 5 discontinued after treatment switch 100 MS-DMT arm participants discontinued before treatment switch: 57 discontinued before treatment switch, and 43 discontinued after treatment switch
| Milestone | Fingolimod | Disease Modifying Therapy |
|---|---|---|
| Started | 436 | 439 |
| On randomized treatment | 352 | 125 |
| On switched treatment | 22 | 214 |
| Completed | 374 | 339 |
| Not completed | 62 | 100 |
| Withdrew: Abnormal laboratory values | 2 | 0 |
| Withdrew: Administrative problems | 9 | 13 |
| Withdrew: Adverse event | 20 | 29 |
| Withdrew: Death | 0 | 2 |
| Withdrew: Lost to follow-up | 12 | 16 |
| Withdrew: Withdrawal by subject | 13 | 31 |
| Withdrew: Patient no longer requires study drug | 1 | 0 |
| Withdrew: Protocol violation | 0 | 6 |
| Withdrew: Lack of efficacy | 5 | 3 |
Comparison effectiveness of fingolimod versus approved first-line disease modifying therapies by measuring the rate of participant retention on randomized treatment over a 12-month period (Full analysis set)
| participants | Fingolimod | Disease Modifying Therapy (MS-DMT) |
|---|---|---|
| Participant Retention Rate Over 12 Months | 352 | 125 |
Reasons for discontinuation in participants treated with fingolimod vs. DMT over 12 months of treatment Total discontinued (Primary reason): Fingolimod arm: 27, MS-DMT arm: 27 = 54 participants Total discontinued (Secondary reason): Fingolimod arm: 257, MS-DMT arm: 256 = 513 participants Throughout the study, investigators evaluated each patient for occurrence of randomized treatment discontinuation and determined the primary and secondary reasons for such discontinuation. At every visit, the investigator evaluated the patients and determined if they should continue on randomized treatment or change to alternative treatment. Treatment discontinuation was a clinically meaningful measure related to safety, efficacy, and tolerability over time, reflecting the therapeutic effectiveness of study treatment.
| participants | Fingolimod | Disease Modifying Therapy (MS-DMT) |
|---|---|---|
| Occurrence of relapse (Primary reason) | 5 | 14 |
| Disease activity present in MRI (Primary reason) | 0 | 6 |
| Injection site reaction (Primary reason) | 0 | 61 |
| Flu-like symptoms (Primary reason) | 0 | 34 |
| Lipoatrophy (Primary reason) | 0 | 1 |
| Depression (Primary reason) | 1 | 4 |
| Hepatic side effects (Primary reason) | 7 | 3 |
| Spasticity (Primary reason) | 0 | 1 |
| Infection (Primary reason) | 0 | 0 |
| Macular edema (Primary reason) | 1 | 0 |
| Bradycardia (Primary reason) | 0 | 0 |
| Needle phobia (Primary reason) | 0 | 13 |
| Inconvenient administration (Primary reason) | 0 | 33 |
| Frequency of injections (Primary reason) | 0 | 29 |
| Neutralizing antibodies present (Primary reason) | 0 | 0 |
| Other (Primary reason) | 13 | 58 |
| Occurrence of relapse (Secondary reason) | 0 | 3 |
| Disease activity present in MRI (Secondary reason) | 2 | 5 |
| Injection site reaction (Secondary reason) | 0 | 40 |
| Flu-like symptoms (Secondary reason) | 1 | 16 |
| Lipoatrophy (Secondary reason) | 0 | 1 |
| Depression (Secondary reason) | 0 | 6 |
| Hepatic side effects (Secondary reason) | 5 | 0 |
| Spasticity (Secondary reason) | 1 | 2 |
| Infection (Secondary reason) | 0 | 0 |
| Macular edema (Secondary reason) | 1 | 0 |
| Bradycardia (Secondary reason) | 0 | 0 |
| Needle phobia (Secondary reason) | 0 | 18 |
| Inconvenient administration (Secondary reason) | 0 | 55 |
| Frequency of injections (Secondary reason) | 0 | 45 |
| Neutralizing antibodies present (Secondary reason) | 0 | 0 |
| Other (Secondary reason) | 17 | 65 |
Summary statistics Compare cognitive impairment measured by Symbol Digit Modalities Test (SDMT) scores. The SDMT score and its change from baseline value were summarized by visit. For the change from baseline values at each visit, ANCOVA adjusted for treatment naivety, corresponding baseline values, and age was performed for treatment comparisons The SDMT measures the time to pair abstract symbols with specific numbers. The test requires elements of attention, visuoperceptual processing, working memory, and psychomotor speed. The score is the number of correctly coded items from 0-110 in 90 seconds. The total score provides a measure of the speed and accuracy of symbol-digit substitution. NOTE: Higher scores indicate better performance.
| SDMT score | Fingolimod | Disease Modifying Therapy (MS-DMT) |
|---|---|---|
| Baseline (n=76,70) | 52.00 ± 12.12 | 51.60 ± 13.40 |
| Change at 6 months (n=70,64) | 2.20 ± 8.09 | 0.20 ± 10.13 |
| Change at 12 months (n=58, 18) | 3.20 ± 7.09 | 1.40 ± 8.33 |
| Change at Last assessment (n=73, 65) | 3.30 ± 7.77 | 0.40 ± 9.47 |
Summary statistics Compare cognitive impairment measured by Symbol Digit Modalities Test (SDMT) scores. The SDMT score and its change from baseline value were summarized by visit. For the change from baseline values at each visit, ANCOVA adjusted for treatment naivety, corresponding baseline values, and age was performed for treatment comparisons The SDMT measures the time to pair abstract symbols with specific numbers. The test requires elements of attention, visuoperceptual processing, working memory, and psychomotor speed. The score is the number of correctly coded items from 0-110 in 90 seconds. The total score provides a measure of the speed and accuracy of symbol-digit substitution. NOTE: Higher scores indicate better performance.
| SDMT score | Fingolimod | Disease Modifying Therapy (MS-DMT) |
|---|---|---|
| Baseline (n=355,348) | 48.90 ± 18.26 | 48.50 ± 20.19 |
| Change at 6 months (n=339,322) | -0.50 ± 14.04 | 0.70 ± 13.16 |
| Change at 12 months (n=282,105) | 0.70 ± 16.02 | 0.40 ± 14.90 |
| Change at Last assessment (n=342, 324) | 0.80 ± 16.27 | 0.70 ± 13.95 |
Summary statistics for percent change from month 12 in brain volume by visit (Randomized treatment / randomized phase) in patients treated with fingolimod vs.DMTs as measured by MRI
| percent change in brain volume | Fingolimod | Disease Modifying Therapy |
|---|---|---|
| Percent change at 12 months (n=323, 111) | -0.396 ± 0.7825 | -0.555 ± 0.7181 |
| Percent change at Last assessment (n=370, 246) | -0.385 ± 0.7690 | -0.420 ± 0.6423 |
Summary statistics for Medication Satisfaction Questionnaire\[Question: "Overall, how satisfied are you with your current medication?"\] (Randomized treatment / randomized phase): Fingolimod vs MS-DMT
| participants | Fingolimod | Disease Modifying Therapy (DS-DMT) |
|---|---|---|
| Baseline, Extremely dissatisfied | 10 ± 4.7 | 16 ± 7.2 |
| Baseline, Very dissatisfied | 22 ± 10.3 | 13 ± 5.8 |
| Baseline, Somewhat dissatisfied | 29 ± 13.6 | 39 ± 17.5 |
| Baseline, Neither dissatisfied nor satisfied | 62 ± 29.0 | 61 ± 27.4 |
| Baseline, Somewhat satisfied | 35 ± 16.4 | 46 ± 20.6 |
| Baseline, Very satisfied | 42 ± 19.6 | 31 ± 13.9 |
| Baseline, Extremely satisfied | 14 ± 6.5 | 17 ± 7.6 |
| Baseline, Missing | 219 ± 0 | 205 ± 0 |
| 1 month, Extremely dissatisfied | 8 ± 1.9 | 29 ± 6.9 |
| 1 month, Very dissatisfied | 14 ± 3.3 | 37 ± 8.9 |
| 1 month, Somewhat dissatisfied | 8 ± 1.9 | 52 ± 12.4 |
| 1 month, Neither dissatisfied nor satisfied | 32 ± 7.5 | 74 ± 17.7 |
| 1 month, Somewhat satisfied | 52 ± 12.1 | 89 ± 21.3 |
| 1 month, Very satisfied | 161 ± 37.5 | 97 ± 23.2 |
| 1 month, Extremely satisfied | 154 ± 35.9 | 40 ± 9.6 |
| 1 month, Missing | 4 ± 0 | 10 ± 0 |
| 3 months, Extremely dissatisfied | 5 ± 1.2 | 19 ± 5.5 |
| 3 months, Very dissatisfied | 11 ± 2.7 | 38 ± 11.0 |
| 3 months, Somewhat dissatisfied | 11 ± 2.7 | 42 ± 12.1 |
| 3 months, Neither dissatisfied nor satisfied | 46 ± 11.1 | 53 ± 15.3 |
| 3 months, Somewhat satisfied | 43 ± 10.4 | 73 ± 21.1 |
| 3 months, Very satisfied | 153 ± 37.0 | 91 ± 26.3 |
| 3 months, Extremely satisfied | 144 ± 34.9 | 30 ± 8.7 |
| 3 months, Missing | 20 ± 0 | 82 ± 0 |
| 6 months, Extremely dissatisfied | 8 ± 2.0 | 9 ± 4.6 |
| 6 months, Very dissatisfied | 15 ± 3.8 | 11 ± 5.6 |
| 6 months, Somewhat dissatisfied | 11 ± 2.8 | 13 ± 6.6 |
| 6 months, Neither dissatisfied nor satisfied | 25 ± 6.3 | 24 ± 12.2 |
| 6 months, Somewhat satisfied | 57 ± 14.4 | 46 ± 23.5 |
| 6 months, Very satisfied | 130 ± 32.7 | 67 ± 34.2 |
| 6 months, Extremely satisfied | 151 ± 38.0 | 26 ± 13.3 |
| 6 months, Missing | 36 ± 0 | 232 ± 0 |
| 9 months, Extremely dissatisfied | 7 ± 1.9 | 4 ± 2.6 |
| 9 months, Very dissatisfied | 8 ± 2.2 | 6 ± 3.9 |
| 9 months, Somewhat dissatisfied | 12 ± 3.2 | 12 ± 7.8 |
| 9 months, Neither dissatisfied nor satisfied | 21 ± 5.7 | 15 ± 9.8 |
| 9 months, Somewhat satisfied | 42 ± 11.4 | 29 ± 19.0 |
| 9 months, Very satisfied | 135 ± 36.5 | 58 ± 37.9 |
| 9 months, Extremely satisfied | 145 ± 39.2 | 29 ± 19.0 |
| 9 months, Missing | 63 ± 0 | 275 ± 0 |
| 12 months, Extremely dissatisfied | 7 ± 2.0 | 3 ± 2.4 |
| 12 months, Very dissatisfied | 7 ± 2.0 | 4 ± 3.1 |
| 12 months, Somewhat dissatisfied | 11 ± 3.1 | 4 ± 3.1 |
| 12 months, Neither dissatisfied nor satisfied | 27 ± 7.7 | 8 ± 6.3 |
| 12 months, Somewhat satisfied | 34 ± 9.7 | 22 ± 7.3 |
| 12 months, Very satisfied | 115 ± 32.8 | 60 ± 47.2 |
| 12 months, Extremely satisfied | 150 ± 42.7 | 26 ± 20.5 |
| 12 months, Missing | 82 ± 0 | 301 ± 0 |
| Last assessment, Extremely dissatisfied | 14 ± 3.3 | 46 ± 10.9 |
| Last assessment, Very dissatisfied | 15 ± 3.5 | 61 ± 14.5 |
| Last assessment, Somewhat dissatisfied | 23 ± 5.3 | 57 ± 13.5 |
| Last assessment,Neither dissatisfied nor satisfied | 45 ± 10.5 | 58 ± 13.7 |
| Last assessment, Somewhat satisfied | 43 ± 10.0 | 69 ± 16.4 |
| Last assessment, Very satisfied | 128 ± 29.8 | 94 ± 22.3 |
| Last assessment, Extremely satisfied | 162 ± 37.7 | 37 ± 8.8 |
| Last assessment, Missing | 3 ± 0 | 6 ± 0 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Fingolimod | — | 29/433 (6.7%) | 282/433 (65.1%) |
| MS DMT | — | 15/428 (3.5%) | 291/428 (68%) |
| Event | Fingolimod | MS DMT |
|---|---|---|
| Multiple sclerosis relapseNervous system disorders | 5/433 | 5/428 |
| AnxietyPsychiatric disorders | 1/433 | 2/428 |
| PneumoniaInfections and infestations | 2/433 | 0/428 |
| DehydrationMetabolism and nutrition disorders | 2/433 | 0/428 |
| Suicidal ideationPsychiatric disorders | 2/433 | 0/428 |
| LeukocytosisBlood and lymphatic system disorders | 0/433 | 1/428 |
| Cardio-respiratory arrestCardiac disorders | 0/433 | 1/428 |
| Abdominal painGastrointestinal disorders | 0/433 | 1/428 |
| Gastrooesophageal reflux diseaseGastrointestinal disorders | 0/433 | 1/428 |
| Umbilical herniaGastrointestinal disorders | 0/433 | 1/428 |
| Event | Fingolimod | MS DMT |
|---|---|---|
| Influenza like illnessGeneral disorders | 12/433 | 64/428 |
| Injection site painGeneral disorders | 0/433 | 62/428 |
| Injection site reactionGeneral disorders | 0/433 | 50/428 |
| FatigueGeneral disorders | 49/433 | 33/428 |
| Injection site erythemaGeneral disorders | 0/433 | 42/428 |
| HeadacheNervous system disorders | 40/433 | 41/428 |
| NasopharyngitisInfections and infestations | 41/433 | 22/428 |
| DizzinessNervous system disorders | 31/433 | 12/428 |
| Injection site pruritusGeneral disorders | 0/433 | 30/428 |
| LymphopeniaBlood and lymphatic system disorders | 30/433 | 1/428 |
Randomized set (RS): consists of all patients who were assigned randomization numbers. The participants in this set were called randomized participants. This set was used to summarize participant disposition, demographic and baseline characteristics, and protocol deviation information. Participants were grouped according to randomized treatment.
| Age, Continuous(years) | Fingolimod | Disease Modifying Therapy (MS_DMT) | Total |
|---|---|---|---|
| Mean | 41.5 ± 10.84 | 41.9 ± 10.39 | 41.7 ± 10.61 |
| Sex: Female, Male(Participants) | Fingolimod | Disease Modifying Therapy (MS_DMT) | Total |
|---|---|---|---|
| Female | 311 | 329 | 640 |
| Male | 125 | 110 | 235 |
Showing the first 100 of 123 sites across 2 countries. Choose a country and city above to see the rest.
Ran from Jun 2012 to primary completion in Jul 2015, 37 months.
Results were first posted in Jan 2018, 2 years 5 months after primary completion.
Of 28 phase 4 interventional studies under Multiple Sclerosis, Relapsing-Remitting, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 66. This study's 37 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Fingolimod
Multiple Sclerosis, Relapsing-Remitting →